TRT for women: separating real benefits from hype

What did @drmaryclaire actually say?

@drmaryclaire told a follower to "stop taking it immediately" because "unopposed estrogen without progesterone puts you at risk for endometrial hyperplasia and potentially endometrial malignancy" unless the person has "a progesterone containing IUD." The claim is direct: estrogen without progestogen protection is dangerous, and the fix is to stop immediately.

She's talking about a real and well-documented clinical problem. Unopposed systemic estrogen in women with an intact uterus is not a fringe concern. It's one of the most established safety signals in hormone therapy. The question is whether the advice she gave is complete, accurate, and appropriate for a TikTok comment response.

Does the science back this up?

The core warning is solid. Decades of research confirm that systemic estrogen without adequate progestogen protection significantly increases endometrial cancer risk in women with a uterus. The science here is not subtle.

The landmark PEPI trial (Writing Group for the PEPI Trial, 1996, JAMA) found that unopposed estrogen caused endometrial hyperplasia in 62% of women over three years, compared to less than 4% in those on combined regimens. That's not a marginal difference. The Women's Health Initiative also documented elevated endometrial cancer risk with estrogen-only therapy in women who still had a uterus. Current clinical guidelines from the Endocrine Society and NAMS are unambiguous: progestogen co-administration is required for endometrial protection in women with an intact uterus using systemic estrogen. Her warning is grounded in real data.

The levonorgestrel IUD as a progestogen delivery method for endometrial protection is also legitimate. Studies including Varila et al. (1995, Fertility and Sterility) support its use as an alternative to oral or transdermal progestogen in women on estrogen therapy.

What did they get wrong (or right)?

She got the core risk right. Unopposed estrogen is genuinely dangerous for the endometrium, and that warning deserves to be stated clearly. Credit where it's due.

What's missing is nuance that matters clinically. The advice to "stop taking it immediately" sidesteps a more accurate recommendation: the patient should consult a prescriber and likely add progestogen rather than simply discontinue. Abrupt estrogen cessation has its own consequences, including vasomotor symptom rebound, and more importantly, it doesn't address whether hyperplasia has already developed. If someone has been on unopposed estrogen, the clinical response is not just to stop, it's to evaluate the endometrium and correct the regimen.

She also doesn't specify whether she means systemic estrogen or localized vaginal estrogen, which has a different risk profile. Low-dose vaginal estrogen generally does not require progestogen co-administration per NAMS 2020 position statements. That distinction matters and is absent here. Giving blanket stop-immediately advice in a comment section, without knowing the dose, duration, or formulation, is the kind of thing that gets people into trouble.

What should you actually know?

If you have a uterus and have been prescribed systemic estrogen without progestogen protection, that is a clinical error that needs to be corrected, not just stopped. The right move is to contact the prescriber immediately, not to self-discontinue and assume the problem is solved.

Endometrial hyperplasia can develop silently. Stopping estrogen does not reverse hyperplasia that may have already started. Anyone who has been on unopposed systemic estrogen for an extended period may need endometrial evaluation, which typically means a transvaginal ultrasound or biopsy depending on clinical history.

The levonorgestrel IUD (like Mirena) is an accepted option for endometrial protection in women using systemic estrogen, but it needs to be in place and hormonally active. It's not a retroactive fix.

Low-dose vaginal estrogen for GSM (genitourinary syndrome of menopause) is a different conversation. NAMS 2020 guidelines indicate that progestogen is generally not required for low-dose vaginal preparations because systemic absorption is minimal. If that's what the original commenter was asking about, this entire warning may not apply to them, and that ambiguity should have been flagged.